Literature DB >> 23337092

The longitudinal course of attention deficit/hyperactivity disorder in velo-cardio-facial syndrome.

Kevin M Antshel1, Kaitlin Hendricks, Robert Shprintzen, Wanda Fremont, Anne Marie Higgins, Stephen V Faraone, Wendy R Kates.   

Abstract

OBJECTIVE: To evaluate predictors of persistence of attention deficit/hyperactivity disorder (ADHD) in a large sample of children with velo-cardio-facial syndrome (VCFS) with and without ADHD followed prospectively into adolescence. STUDY
DESIGN: Children with VCFS with (n = 37) and without (n = 35) ADHD who were on average 11 years old at the baseline assessment and 15 years old at the follow-up assessment were comprehensively assessed with structured diagnostic interviews and assessments of behavioral, cognitive, social, school, and family functioning. Control participants both with and without ADHD were also followed prospectively.
RESULTS: In adolescence, 65% of children with VCFS continued to have findings consistent with ADHD. Childhood predictors of persistence were higher rates of familial ADHD, having childhood depression, having higher levels of hyperactivity, and a larger number of intrusion errors on a verbal list learning test at baseline. Approximately 15% of children with VCFS who did not have ADHD at Time 1 met diagnostic criteria for ADHD at Time 2. All of these children had subthreshold ADHD symptoms at Time 1.
CONCLUSIONS: These findings prospectively confirm that persistence of ADHD into adolescence in VCFS is predicted by childhood variables that have been previously documented in the non-VCFS ADHD literature.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23337092      PMCID: PMC3692611          DOI: 10.1016/j.jpeds.2012.12.026

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  53 in total

1.  Defining the clinical spectrum of deletion 22q11.2.

Authors:  Nathaniel H Robin; Robert J Shprintzen
Journal:  J Pediatr       Date:  2005-07       Impact factor: 4.406

2.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.

Authors:  J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-07       Impact factor: 8.829

3.  The use of factor analysis for ascertaining patterns of psychopathology in children with intellectual disability.

Authors:  B J Tonge; S L Einfeld; J Krupinski; A Mackenzie; M McLaughlin; T Florio; R J Nunn
Journal:  J Intellect Disabil Res       Date:  1996-06

4.  Educational and occupational outcome of hyperactive boys grown up.

Authors:  S Mannuzza; R G Klein; A Bessler; P Malloy; M E Hynes
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-09       Impact factor: 8.829

5.  A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders.

Authors:  J Biederman; S Faraone; S Milberger; J Guite; E Mick; L Chen; D Mennin; A Marrs; C Ouellette; P Moore; T Spencer; D Norman; T Wilens; I Kraus; J Perrin
Journal:  Arch Gen Psychiatry       Date:  1996-05

6.  Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication.

Authors:  Ronald C Kessler; Lenard A Adler; Russell Barkley; Joseph Biederman; C Keith Conners; Stephen V Faraone; Laurence L Greenhill; Savina Jaeger; Kristina Secnik; Thomas Spencer; T Bedirhan Ustün; Alan M Zaslavsky
Journal:  Biol Psychiatry       Date:  2005-06-01       Impact factor: 13.382

7.  Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis.

Authors:  Warrick J Brewer; Shona M Francey; Stephen J Wood; Henry J Jackson; Christos Pantelis; Lisa J Phillips; Alison R Yung; Vicki A Anderson; Patrick D McGorry
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

Review 8.  Issues in the taxonomy of psychopathology in mental retardation.

Authors:  S L Einfeld; M Aman
Journal:  J Autism Dev Disord       Date:  1995-04

9.  Association of neuropsychological vulnerability markers in relatives of schizophrenic patients.

Authors:  R Toomey; S V Faraone; L J Seidman; W S Kremen; J R Pepple; M T Tsuang
Journal:  Schizophr Res       Date:  1998-05-25       Impact factor: 4.939

10.  Hillside study of risk and early detection in schizophrenia.

Authors:  B Cornblatt; M Obuchowski; D Schnur; J D O'Brien
Journal:  Br J Psychiatry Suppl       Date:  1998
View more
  10 in total

Review 1.  Genetics in child and adolescent psychiatry: methodological advances and conceptual issues.

Authors:  Sarah Hohmann; Nicoletta Adamo; Benjamin B Lahey; Stephen V Faraone; Tobias Banaschewski
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-04-08       Impact factor: 4.785

Review 2.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

3.  Altered Brain Structure-Function Relationships Underlie Executive Dysfunction in 22q11.2 Deletion Syndrome.

Authors:  Rachel K Jonas; Maria Jalbrzikowski; Caroline A Montojo; Arati Patel; Leila Kushan; Carolyn C Chow; Therese Vesagas; Carrie E Bearden
Journal:  Mol Neuropsychiatry       Date:  2015-12-04

4.  Longitudinal study of cerebral surface morphology in youth with 22q11.2 deletion syndrome, and association with positive symptoms of psychosis.

Authors:  Petya D Radoeva; Ravi Bansal; Kevin M Antshel; Wanda Fremont; Bradley S Peterson; Wendy R Kates
Journal:  J Child Psychol Psychiatry       Date:  2016-10-27       Impact factor: 8.982

5.  Young Adult Outcomes for Children With 22q11 Deletion Syndrome and Comorbid ADHD.

Authors:  Lea E Taylor; Wendy R Kates; Wanda Fremont; Kevin M Antshel
Journal:  J Pediatr Psychol       Date:  2018-07-01

Review 6.  22q11 deletion syndrome: a review of the neuropsychiatric features and their neurobiological basis.

Authors:  Chiara Squarcione; Maria Chiara Torti; Fabio Di Fabio; Massimo Biondi
Journal:  Neuropsychiatr Dis Treat       Date:  2013-12-04       Impact factor: 2.570

7.  Frontal dysconnectivity in 22q11.2 deletion syndrome: an atlas-based functional connectivity analysis.

Authors:  Leah M Mattiaccio; Ioana L Coman; Carlie A Thompson; Wanda P Fremont; Kevin M Antshel; Wendy R Kates
Journal:  Behav Brain Funct       Date:  2018-01-20       Impact factor: 3.759

8.  Selective Effects of Methylphenidate on Attention and Inhibition in 22q11.2 Deletion Syndrome: Results From a Clinical Trial.

Authors:  Johanna Maeder; Valentina Mancini; Corrado Sandini; Fiona Journal; Maude Schneider; Matthias Kliegel; Stephan Eliez
Journal:  Int J Neuropsychopharmacol       Date:  2022-03-17       Impact factor: 5.176

Review 9.  Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

Authors:  Maude Schneider; Martin Debbané; Anne S Bassett; Eva W C Chow; Wai Lun Alan Fung; Marianne van den Bree; Michael Owen; Kieran C Murphy; Maria Niarchou; Wendy R Kates; Kevin M Antshel; Wanda Fremont; Donna M McDonald-McGinn; Raquel E Gur; Elaine H Zackai; Jacob Vorstman; Sasja N Duijff; Petra W J Klaassen; Ann Swillen; Doron Gothelf; Tamar Green; Abraham Weizman; Therese Van Amelsvoort; Laurens Evers; Erik Boot; Vandana Shashi; Stephen R Hooper; Carrie E Bearden; Maria Jalbrzikowski; Marco Armando; Stefano Vicari; Declan G Murphy; Opal Ousley; Linda E Campbell; Tony J Simon; Stephan Eliez
Journal:  Am J Psychiatry       Date:  2014-06       Impact factor: 18.112

10.  The emergence of psychotic experiences in the early adolescence of 22q11.2 Deletion Syndrome.

Authors:  Samuel J R A Chawner; Maria Niarchou; Joanne L Doherty; Hayley Moss; Michael J Owen; Marianne B M van den Bree
Journal:  J Psychiatr Res       Date:  2018-11-05       Impact factor: 5.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.